tbuckley/cabot-search huggingface dataset:
26085 Key efficacy and safety of apremilast in patients with mild to moderate plaque psoriasis in the phase 3 ADVANCE trial
Authors: Kristina Callis Duffin, Linda Stein Gold, Craig Leonardi, David Pariser, Lawrence Green, Howard Sofen, Bruce Strober, Mindy Chen, Amgen Inc;Yao Wang, Kim Papp
Journal: Journal of the American Academy of Dermatology (2021)
Abstract 14416: Strategies for Improving the Care of Patients Hospitalized With Heart Failure: Baseline Data From the CONNECT-HF Trial
Authors: Kent Y Feng, Bradi B Granger, Gregg C Fonarow, Ileana L Pina, Eldrin F Lewis, Lauren B Cooper, Larry A Allen, Lisa A Kaltenbach, Christopher B Granger, Adrian F Hernandez, Adam D DeVore
Journal: Circulation (2018)

Introduction: Patients hospitalized for heart failure (HF) are at an increased risk of rehospitalization and death following discharge. However, limited data exist to inform health systems on imple...
Defining baseline variability of serum tryptase levels improves accuracy in identifying anaphylaxis
Authors: Allyson Mateja, Qinlu Wang, Jack Chovanec, Jiwon Kim, Kenneth J Wilson, Lawrence B Schwartz, Sarah C Glover, Melody C Carter, Dean D Metcalfe, Erica Brittain, Jonathan J Lyons
Journal: Journal of Allergy and Clinical Immunology (2021)
26918 Describing real-world pediatric psoriasis patients in the US and EU5
Authors: Nadine Chapman-Rothe, Craig Richardson, Amie Scott, Haijun Tian, Fetske Van Der Meulen, Teresa Bachhuber, Steve Lobosco, James Lucas, Sophie Meakin, James Hetherington, James Piercy
Journal: Journal of the American Academy of Dermatology (2021)
Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study
Authors: Yuan-Yuan Qu, Hai-Liang Zhang, Hongqian Guo, Hong Luo, Qing Zou, Nianzeng Xing, Shujie Xia, Zhongquan Sun, Xuepei Zhang, Chaohong He, Jinling Cai, Xiao Zhang, Quanren Wang, Ding-Wei Ye
Journal: Clinical Cancer Research (2021)

Blockade of immune checkpoint and angiogenesis is an effective treatment strategy for advanced or metastatic renal cell carcinoma (RCC). We report the results of camrelizumab plus famitinib in the RCC cohort of an open-label, multicenter, phase II basket study.Eligible patients were enrolled to receive camrelizumab (200 mg i.v. every 3 weeks) and famitinib (20 mg orally once daily). Primary endpoint was objective response rate (ORR) per RECIST version 1.1.Totally, 38 patients were recruited, including 13 (34.2%) treatment-naïve and 25 (65.8%) previously treated patients. With a median duration from enrollment to data cutoff of 16.5 months (range, 6.1-20.4), 23 patients achieved a confirmed objective response, and ORR was 60.5% [95% confidence interval (CI), 43.4-76.0]. Responses in 18 (78.3%) responders were still ongoing, and Kaplan-Meier estimated median duration of response had not been reached yet (range, 1.0+-14.8+ months). Median progression-free survival (PFS) was 14.6 months (95% CI, 6.2-not reached). ORR was 84.6% (95% CI, 54.6-98.1) in treatment-naïve patients and 48.0% (95% CI, 27.8-68.7) in pretreated patients; median PFS had not been reached and was 13.4 months (95% CI, 4.1-not reached), respectively. Most common grade 3 or 4 treatment-related adverse events included proteinuria (18.4%), hypertension (18.4%), decreased neutrophil count (13.2%), palmar-plantar erythrodysesthesia syndrome (10.5%), and hypertriglyceridemia (10.5%). No treatment-related deaths occurred, and no new safety signals were observed.Camrelizumab plus famitinib showed potent and enduring antitumor activity in patients with advanced or metastatic RCC, both in treatment-naïve and previously treated population.
Public health is key to data saving lives
Authors: Sebastian Walsh
Journal: BMJ (2021)

In response to the Department of Health and Social Care’s policy paper “Data saves lives,”1 Scott and colleagues point out that data save lives only if they inform practice, citing examples from healthcare and social care.2 However, public health is key because the social determinants of health account for most health outcomes.34

Public Health England maintains the excellent Fingertips resource, which is freely accessible …
Inhibition of PDIA3 in club cells attenuates osteopontin production and lung fibrosis
Authors: Amit Kumar, Evan Elko, Sierra R Bruno, Zoe F Mark, Nicolas Chamberlain, Bethany Korwin Mihavics, Ravishankar Chandrasekaran, Joseph Walzer, Mona Ruban, Clarissa Gold, Ying Wai Lam, Sudhir Ghandikota, Anil G Jegga, Jose L Gomez, Yvonne MW Janssen-Heininger, Vikas Anathy
Journal: Thorax (2021)

The role of club cells in the pathology of idiopathic pulmonary fibrosis (IPF) is not well understood. Protein disulfide isomerase A3 (PDIA3), an endoplasmic reticulum-based redox chaperone required for the functions of various fibrosis-related proteins; however, the mechanisms of action of PDIA3 in pulmonary fibrosis are not fully elucidated.To examine the role of club cells and PDIA3 in the pathology of pulmonary fibrosis and the therapeutic potential of inhibition of PDIA3 in lung fibrosis.Role of PDIA3 and aberrant club cells in lung fibrosis was studied by analyses of human transcriptome dataset from Lung Genomics Research Consortium, other public resources, the specific deletion or inhibition of PDIA3 in club cells and blocking SPP1 downstream of PDIA3 in mice.PDIA3 and club cell secretory protein (SCGB1A1) signatures are upregulated in IPF compared with control patients. PDIA3 or SCGB1A1 increases also correlate with a decrease in lung function in patients with IPF. The bleomycin (BLM) model of lung fibrosis showed increases in PDIA3 in SCGB1A1 cells in the lung parenchyma. Ablation of Pdia3, specifically in SCGB1A1 cells, decreases parenchymal SCGB1A1 cells along with fibrosis in mice. The administration of a PDI inhibitor LOC14 reversed the BLM-induced parenchymal SCGB1A1 cells and fibrosis in mice. Evaluation of PDIA3 partners revealed that SPP1 is a major interactor in fibrosis. Blocking SPP1 attenuated the development of lung fibrosis in mice.Our study reveals a new relationship with distally localised club cells, PDIA3 and SPP1 in lung fibrosis and inhibition of PDIA3 or SPP1 attenuates lung fibrosis.
Sarcopenia as a predictor of perioperative outcomes following radical cystectomy in a contemporary cohort of patients with bladder cancer.
Authors: Nicholas Brent Drury, William Mills Worrilow, Hamza Mustafa Beano, Myra M. Robinson, Jeffrey Ignatoff, Peter Britt, Jessica Wilder, Caitlin Hensel, Dana Sylvestre, Kris E Gaston, Peter E Clark, Stephen Boyd Riggs
Journal: Journal of Clinical Oncology (2019)

e16031 Background: Sarcopenia has gained considerable recognition as an important prognostic factor for complications, longer hospital stay, and survival following cystectomy for bladder cancer. However, inconsistent cutoff values to define sarcopenia have been utilized throughout the literature. Our aim was to evaluate sarcopenia as a predictor of outcomes following radical cystectomy with urinary diversion (RCUD) using the international consensus definition, Martin criteria, and Mayr criteria, as a standardized cutoff value would potentially reduce bias across studies. Methods: A retrospective analysis of patients treated with RCUD at our institution between 2010 and 2017 was performed. Sarcopenia was defined according to the aforementioned criteria and assessed by measuring total psoas area (TPA) on preoperative computerized tomography. The impact of sarcopenia on perioperative outcomes, cancer-specific survival (CSS), and overall survival (OS) was evaluated with univariate and multivariate regression models. Results: Of 258 patients who underwent RCUD, 195 had available computed tomography scans within 90 days of surgery. The median TPA scores among men and women were 578.0 and 459.6 mm 2 /mm 2 , respectively. The overall incidence of sarcopenia according to the international consensus definition, Martin criteria, and Mayr criteria was 36.4% (71/195), 24.1% (47/195), and 31.3% (61/195), respectively. Regardless of definition, significant differences were not observed in length of stay, high grade complications, readmissions, and discharge destination (all P &gt; .05). Furthermore, sarcopenia was not significantly associated with CSS or OS. The median follow-up time was 4.1 years (95% CI: 3.6 - 4.4). The 5-year CSS and OS were 46.3% and 66.2%, respectively. Conclusions: Irrespective of definition, we were unable to externally validate sarcopenia as a predictor of perioperative outcomes in our contemporary cohort. Future studies will evaluate the impact of our evolving perioperative care pathway on oncological outcomes, including its ability to mitigate the effects of sarcopenia through reducing the physiological and mental demands of surgery.
27529 Safety of guselkumab in patients with psoriatic arthritis through 1 year: Pooled findings from DISCOVER-1 and DISCOVER-2 phase 3 trials
Authors: Christopher T. Ritchlin, Proton Rahman, Philip S. Helliwell, Wolf-Henning Boehncke, Iain McInnes, Alice B. Gottlieb, Alexa P. Kollmeier, May Shawi, Bei Zhou, Philip J. Mease
Journal: Journal of the American Academy of Dermatology (2021)
心臓足首血管指数(CAVI)はアテローム血栓性卒中を引き起こす大動脈アーチプラークを予測する
Authors: Nishiyama Satoshi, Watanabe Tetsu, Tamura Harutoshi, Sasaki Shintaro, Wanezaki Masahiro, Takahashi Hiroki, Arimoto Takanori, Shishido Tetsuro, Miyashita Takehiko, Miyamoto Takuya, Kubota Isao
Journal: Circulation (2012)
Validation of an At-Home Direct Antigen Rapid Test for COVID-19
Authors: Alexander Harmon, Celina Chang, Nol Salcedo, Brena Sena, Bobby Brooke Herrera, Irene Bosch, Laura E. Holberger
Journal: JAMA Network Open (2021)

This cohort study examines the performance of direct antigen rapid tests compared with that of quantitative real-time polymerase chain reaction for analyzing self-collected nasal specimens for the presence of SARS-CoV-2.
Implementation and Evaluation of a Telemedicine Program for Specialty Care in North Carolina Correctional Facilities
Authors: Saif Khairat, Aaron Bohlmann, Erin Wallace, Adnan Lakdawala, Barbara S. Edson, Terri L. Catlett, Spencer D. Dorn
Journal: JAMA Network Open (2021)

This cross-sectional study evaluates the implementation of a telemedicine program in North Carolina prisons based on responses from individuals who were incarcerated, health care practitioners, and telepresenters.
Exercise hormone irisin is a critical regulator of cognitive function
Authors: Mohammad R. Islam, Sophia Valaris, Michael F. Young, Erin B. Haley, Renhao Luo, Sabrina F. Bond, Sofia Mazuera, Robert R. Kitchen, Barbara J. Caldarone, Luis E. B. Bettio, Brian R. Christie, Angela B. Schmider, Roy J. Soberman, Antoine Besnard, Mark P. Jedrychowski, Hyeonwoo Kim, Hua Tu, Eunhee Kim, Se Hoon Choi, Rudolph E. Tanzi, Bruce M. Spiegelman, Christiane D. Wrann
Journal: Nature Metabolism (2021)
Development of Cardiac Fibrosis in Sphingosine Kinase 1 Transgenic Mice through an S1P3 Receptor-mediated, Reactive Oxygen Species-dependent Process
Authors: Takuwa Noriko, Ohkura Seiichiro, Takashima Shinichiro, Ohtani Keisuke, Okamoto Yasuo, Usui Soichiro, Yoshioka Kazuaki, Takamura Masayuki, Kaneko Shuichi, Takuwa Yo
Journal: Circulation (2010)
Women’s health is made a priority in Scotland
Authors: Bryan Christie
Journal: BMJ (2021)

The UK’s first ever comprehensive plan designed to improve health outcomes for women is set to be implemented in Scotland.

It aims to raise awareness of the needs of girls and women of all ages and make the health service more accessible, inclusive, and responsive.

The Women’s Health Plan1 records many examples of how women are let down by services that have largely been developed around the problems experienced by men. A report from the British Heart Foundation has found that …
Ureteral stents cannot decrease the incidence of ureteroileal anastomotic stricture and leakage: A systematic review and meta-analysis
Authors: Yu-Lu Peng, Kang Ning, Ze-Shen Wu, Zhi-Yong Li, Min-Hua Deng, Long-Bin Xiong, Chun-Ping Yu, Zhi-Ling Zhang, Zhuo-Wei Liu, Hui-Ming Lu, Fang-Jian Zhou
Journal: International Journal of Surgery (2021)

The ileal conduit and ileal orthotopic neobladder were the most popular methods for urinary diversion following radical cystectomy. Stenting the anastomosis of ileo-ureter or ureter-neobladder was a common practice. However, it is still controversial if ureteral stents could prevent complications such as ureteroileal anastomosis stricture (UIAS) and ureteroileal anastomosis leakage (UIAL) after ureteral anastomosis.This study aims to investigate the role of the ureteral stent in preventing UIAS and UIAL.We systematically searched the related studies in PubMed, Embase, and Cochrane Library up to June 2020.Cohort studies that identified the use of stent and the incidence of UIAS or UIAL were recorded.Comparative meta-analysis was conducted on four cohort studies for comparison of UIAS and UIAL between the stented and nonstented groups. Besides, eleven studies which reported the events of UIAS and UIAL were used for meta-analysis of single proportion.A total of 11 studies were qualified for analysis. Comparative meta-analysis identified that the incidence of UIAS was higher in the stented group than that in the nonstented group, but this did not reach a significant difference (odds ratio [OR]: 1.64; 95% confidence interval [CI]: 0.88-3.05; P = 0.12). Besides, there was no difference in the incidences of UIAL between the stented and the nonstented groups. On meta-analysis of single proportion, the incidence of UIAS was 7% (95% CI: 3%-10%) in the stented group and 3% (95% CI: 1%-6%) in the nonstented group. The UIAL rate was 1% (95% CI, 0%-4%) in stented patients and 2% (95% CI, 1%-4%) in nonstented patients.Stenting the ureteroileal anastomosis resulted in a higher incidence of UIAS. There is no evidence to support ureteral stents could prevent the occurrence of UIAL after urinary diversion.
Comparison between labeling method of MDCT and virtual histology of IVUS for non-calcified plaque analysis
Authors: T Kodama, Takeshi Kondo, Tadaaki Orihara, Makoto Kondo, Satoshi Sumino, Masahiko Suguta, Hiroshi Fukazawa, Akitsugu Ohida, Shinichi Takase
Journal: Circulation (2009)
Biomimetic, ROS-detonable nanoclusters — A multimodal nanoplatform for anti-restenotic therapy
Authors: Yi Zhao, Takuro Shirasu, Nisakorn Yodsanit, Eric Kent, Mingzhou Ye, Yuyuan Wang, Ruosen Xie, Alexander Christopher Gregg, Yitao Huang, K. Craig Kent, Lian-Wang Guo, Shaoqin Gong, Bowen Wang
Journal: Journal of Controlled Release (2021)
Reporting of Race and Ethnicity in Medical and Scientific Journals—Reply
Authors: Annette Flanagin, Stacy Christiansen, Tracy Frey
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Covid-19: Fully vaccinated people can carry as much delta virus as unvaccinated people, data indicate
Authors: Shaun Griffin
Journal: BMJ (2021)

Covid-19: Fully vaccinated people can carry as much delta virus as unvaccinated people, data indicate Shaun GriffinAdults who have been fully vaccinated against SARS-CoV-2 can carry the same viral load of the delta variant as those who are unvaccinated, a preliminary analysis of UK data suggests. 11 Pouwels KB, Pritchard E, Matthews PC, et al, for the COVID-19 Infection Survey Team.Impact of delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK.https://www.ndm.ox.ac.uk/covid-19/covid-19-infection-survey/results/newstudies.
Variation in Management of Extremity Soft-Tissue Sarcoma in Younger vs Older Adults
Authors: Crystal Seldon, Gautam Shrivastava, Abdurrahman Al-Awady, David Asher, Stephen Ramey, Melanie Fernandez, Sarah Dooley, Deukwoo Kwon, Wei Zhao, Neha Goel, Tejan Diwanji, Ty Subhawong, Jonathan Trent, Raphael Yechieli
Journal: JAMA Network Open (2021)

<h3>Importance</h3> A large proportion of extremity soft-tissue sarcomas (ESS) occur among young adults, yet this group is underrepresented in clinical trials, resulting in limited data on this population. Younger patients present many complex challenges that affect clinical management. <h3>Objective</h3> To investigate variations in treatment management in young adults vs older adults with ESS. <h3>Design, Setting, and Participants</h3> This multicenter retrospective cohort study used the National Cancer Data Base (NCDB) to identify patients 18 years and older with ESS who received definitive treatment (ie, limb-sparing surgery [LSS] or amputation) between 2004 and 2014. Data analysis was conducted in November 2019. <h3>Exposures</h3> Treatment regimen received among young adults (aged 18-39 years) and older adults (≥40 years) after diagnosis with ESS. <h3>Main Outcomes and Measures</h3> To detect unique factors associated with treatment decisions in young adults with ESS, multivariable analyses used logistic regressions for patterns of treatment and their association with demographic factors and tumor characteristics. <h3>Results</h3> Overall, 8953 patients were identified, and among these, 1280 (14.3%) were young adults. From the full cohort, 4796 patients (53.6%) identified as male and 6615 (73.9%) identified as non-Hispanic White. More young adults than older adults underwent amputation (age 18-39 years, 104 of 1280 [8.1%]; age 40-64 years, 217 of 3937 [5.5%]; aged ≥65 years, 199 of 3736 [5.3%]), but the association was not statistically significant (age ≥65 years, odds ratio [OR], 1.49; 95% CI, 1.00-2.23;<i>P</i> = .05). Young adults were more likely to receive chemotherapy than older patients (age 40-65 years, OR, 0.52; 95% CI, 0.45-0.60;<i>P</i> = .001; ≥65 years, OR, 0.16; 95% CI, 0.12-0.20;<i>P</i> = .001). Conversely, young adults were less likely to receive radiation therapy compared with older patients (age 40-65 years, OR, 1.40; 95% CI, 1.22-1.61;<i>P</i> = .001; ≥65 years, OR, 1.33; 95% CI, 1.10-1.61;<i>P</i> = .003). Unique to younger adults, clinical stage II disease vs stage I and positive surgical margins were not associated with use of radiation therapy (stage II disease: OR, 1.25; 95% CI, 0.81-1.91;<i>P</i> = .31; positive surgical margins: OR, 1.43; 95% CI, 0.93-2.22;<i>P</i> = .11). White Hispanic young adults were less likely than non-Hispanic White young adults to receive radiation therapy (OR, 0.53; 95% CI, 0.36-0.78;<i>P</i> = .002). <h3>Conclusions and Relevance</h3> In this study, young adults with ESS were more likely to receive chemotherapy and less likely to receive radiation therapy than older adults. Further study is warranted to identify the clinical outcomes of these practice disparities.
The potential use of digital health technologies in the African context: a systematic review of evidence from Ethiopia
Authors: Tsegahun Manyazewal, Yimtubezinash Woldeamanuel, Henry M Blumberg, Abebaw Fekadu, Vincent C Marconi
Journal: npj Digital Medicine (2021)

The World Health Organization (WHO) recently put forth a Global Strategy on Digital Health 2020-2025 with several countries having already achieved key milestones. We aimed to understand whether and how digital health technologies (DHTs) are absorbed in Africa, tracking Ethiopia as a key node. We conducted a systematic review, searching PubMed-MEDLINE, Embase, ScienceDirect, African Journals Online, Cochrane Central Registry of Controlled Trials, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform databases from inception to 02 February 2021 for studies of any design that investigated the potential of DHTs in clinical or public health practices in Ethiopia. This review was registered with PROSPERO ( CRD42021240645 ) and it was designed to inform our ongoing DHT-enabled randomized controlled trial (RCT) (ClinicalTrials.gov ID: NCT04216420 ). We found 27,493 potentially relevant citations, among which 52 studies met the inclusion criteria, comprising a total of 596,128 patients, healthy individuals, and healthcare professionals. The studies involved six DHTs: mHealth (29 studies, 574,649 participants); electronic health records (13 studies, 4534 participants); telemedicine (4 studies, 465 participants); cloud-based application (2 studies, 2382 participants); information communication technology (3 studies, 681 participants), and artificial intelligence (1 study, 13,417 participants). The studies targeted six health conditions: maternal and child health (15), infectious diseases (14), non-communicable diseases (3), dermatitis (1), surgery (4), and general health conditions (15). The outcomes of interest were feasibility, usability, willingness or readiness, effectiveness, quality improvement, and knowledge or attitude toward DHTs. Five studies involved RCTs. The analysis showed that although DHTs are a relatively recent phenomenon in Ethiopia, their potential harnessing clinical and public health practices are highly visible. Their adoption and implementation in full capacity require more training, access to better devices such as smartphones, and infrastructure. DHTs hold much promise tackling major clinical and public health backlogs and strengthening the healthcare ecosystem in Ethiopia. More RCTs are needed on emerging DHTs including artificial intelligence, big data, cloud, cybersecurity, telemedicine, and wearable devices to provide robust evidence of their potential use in such settings and to materialize the WHO's Global Strategy on Digital Health.